Unit dosage of apadenoson

Abstract

The present invention provides a unit dosage of Apadenoson, a pharmacological stress agent, and use of the same as a pharmacologic agent for myocardial perfusion imaging.

1 . (canceled) 
     
     
         2 . A method of performing myocardial perfusion imaging of a human patient in need thereof comprising:
 (a) administering by a single intravenous (iv) bolus a unit dose of Apadenoson of between about 76-175 μg wherein the unit dose is independent of the patient's weight;   (b) administering a radionuclide; and   (c) performing a technique to detect the presence of coronary artery stenoses in the patient, to assess the severity of coronary artery stenoses in the mammal, or a combination thereof, so as to diagnose myocardial perfusion abnormalities in the mammal.   
     
     
         3 . The method of  claim 2 , wherein the unit dose further comprises a pharmaceutically acceptable carrier. 
     
     
         4 . The method of  claim 2 , wherein the unit dose is 1 mL in volume. 
     
     
         5 . The method of  claim 2 , wherein the unit dose is 2 mL in volume. 
     
     
         6 . The method of  claim 2 , wherein the unit dose is 3 mL in volume. 
     
     
         7 . The method of  claim 2 , wherein the unit dose is 4 mL in volume. 
     
     
         8 . The method of  claim 2 , wherein the unit dose is 5 mL in volume. 
     
     
         9 . The method of  claim 2 , wherein the unit dose further contains sodium citrate buffer. 
     
     
         10 . The method of  claim 9 , wherein sodium citrate buffer is present in an amount to buffer the unit dose to pH selected from 4.6-5.0. 
     
     
         11 . The method of  claim 9 , wherein sodium citrate buffer is present in an amount to buffer the unit dose to pH 4.8. 
     
     
         12 . The method of  claim 2  wherein the unit dose is provided as a prefilled syringe. 
     
     
         13 . The method of  claim 12 , wherein the dose of Apadenoson is 150 μg. 
     
     
         14 . The method of  claim 12 , wherein the dose of Apadenoson is 175 μg.